Like Cognitive Drug Research, Ltd.

closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/19/2019 via BusinessWire

Audax Group, acquired Corrona, Inc.

synopsis: Audax Private Equity announced that it has recapitalized, in partnership with the management team, Corrona, LLC. Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.
buyer: Audax Group
Audax Group is a leading alternative investment manager with offices in Boston, New York, and San Francisco. Since its founding in 1999, the firm has raised over $24 billion in capital across its Private Equity and Private Debt businesses. "
target parent: Great Point Partners
target: Corrona, Inc.
Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 11/1/2018 via Company Press Release

BioInformatics Inc., acquired Kalorama Information

synopsis: BioInformatics Inc., the premier research and advisory company serving the life science industry, has acquired Kalorama Information from MarketResearch. Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics, imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.
buyer: BioInformatics Inc.
BioInformatics Inc. is the leading research and advisory firm serving the life science, diagnostic and analytical instrument industries. Their expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing and validating corporate acquisitions. "
target parent: MarketResearch.com, Inc.
target: Kalorama Information
Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals. Kalorama only publishes in healthcare.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/6/2017 via Company Press Release

The Access Group, acquired Health Strategies Group

synopsis: Water Street Healthcare Partners, through its subsidiary, The Access Group, has acquired Health Strategies Group. Health Strategies Group is the leader in market access intelligence and customized research for pharmaceutical and biotech professionals. It dissects trends and identifies opportunities to help companies optimize their product access.
buyer parent: Water Street Healthcare Partners
buyer: The Access Group
The Access Group offers a breadth of services to clients, from traditional “block-and-tackle” launch execution tactics to in-depth market assessments. The company is dedicated to complete product life cycle management, creating brand solutions that drive demand across multiple stakeholder channels. "
target: Health Strategies Group
Health Strategies Group offers a dedicated team of research leaders committed to dissecting the trends, identifying customer needs, and pinpointing the barriers and opportunities for biopharma within the evolving health care environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2015 via PR Newswire

Insignia Capital Group, acquired Metanexgen, Inc.

synopsis: Insignia Capital Group announced the acquisition of metanexgen from DFW Capital Partners. Based in Bensalem, PA, metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
buyer: Insignia Capital Group
Insignia Capital is a private equity firm working with lower-middle market companies. Insignia Capital works with a wide variety of companies but their specialty is consumer, business services and healthcare. "
target parent: DFW Capital Partners
target: Metanexgen, Inc.
Metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/12/2014 via Company Press Release

Everyday Health, Inc., will acquire DoctorDirectory.com

synopsis: Everyday Health signed a definitive agreement to acquire DoctorDirectory. Based in North Carolina, DoctorDirectory provides pharmaceutical companies with multi-channel marketing services that target healthcare professionals. DoctorDirectory.com, Inc. also operates as an online directory for finding a doctor by specialty.
buyer: Everyday Health, Inc. (EVDY:$253.92)
Everyday Health, Inc. is a provider of digital health and wellness solutions. They attract consumers and healthcare professionals to their health and wellness properties, and utilize their data and analytics to deliver personalized content experiences and marketing and engagement solutions. "
target: DoctorDirectory.com
DoctorDirectory.com, Inc. operates as an online directory for finding a doctor by specialty. They also provide Healthcare Professionals the opportunity to participate in Market Research and other programs that help shape the healthcare industry.
price ($mm)
$65
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/16/2014 via Company Press Release

BioPharm Communications, LLC, acquired Carson Analytics

synopsis: BioPharm Communications, a portfolio company of Southfield Capital and minority shareholder Boathouse Capital has announced the acquisition of Carson Analytics. Carson Analytics is a leading provider of integrated commercial analytics solutions for the pharmaceutical and biotechnology industries.
buyer parent: Southfield Capital Advisors
buyer: BioPharm Communications, LLC
BioPharm develops promotional medical education programs for customers in the pharmaceutical and biotechnology industries. The company creates robust clinical content in collaboration with key opinion leaders and delivers it to healthcare practitioners through the company's comprehensive suite. "
target: Carson Analytics
Carson Analytics is a leading provider of integrated commercial analytics solutions for the pharmaceutical and biotechnology industries. They provide advanced analytics solutions including forecasting, promotion response analysis and optimization of promotion mix.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/28/2013 via BusinessWire

QPharma, Inc., acquired MD Mindset, LLC

synopsis: QPharma has announced its acquisition of MD Mindset, LLC, a leading physician research firm focused on improving pharmaceutical sales force and marketing effectiveness. The Atlanta, GA-based company will transition operations of MD Snapshot, MD Feedback, MD Fellowship, and iSFE Tracker products and services to Morristown, New Jersey.
buyer: QPharma, Inc.
QPharma provides regulatory compliance and brand support for the pharmaceutical, medical device and other life sciences industries. Sample services include remediation consulting, validation services, project management & auditing, aggregate spend reporting, sample accountability & online training. "
target: MD Mindset, LLC
MD Mindset, founded in 2001, was established to help pharmaceutical and life sciences sales professionals maximize their performance and effectiveness when calling on healthcare professionals for sales details.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/23/2012 via BusinessWire

ImpactRx, Inc., acquired AlphaDetail, Inc.

synopsis: ImpactRx, a Symphony Technology Group company, and the pioneer in measuring the impact of promotion on physicians’ attitudes and prescribing behavior, announced that it has acquired AlphaDetail, Inc., a leader in global healthcare primary market research and influence network mapping.
buyer parent: Symphony Technology Group
buyer: ImpactRx, Inc.
ImpactRx is the leading provider of consultative and analytically-based promotional effectiveness solutions to the healthcare industry. ImpactRx's ImpactData™ is the industry’s sole source of continuous-capture market promotion and physician treatment data. "
target: AlphaDetail, Inc.
AlphaDetail is a rapidly growing global market research consulting company focused on the pharmaceutical and biotechnology industry. It uses the Internet as a channel to enable rapid, convenient, and effective communication between pharmaceutical companies, healthcare professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/28/2016 via BNC Analysis

AplusA, acquired Bell Falla & Associates LLC

synopsis: AplusA buys Bell Falla to become a leading international marketing research for the pharmaceutical industry and the health sector. Bell Falla is an international market research and consulting firm for pharmaceutical, biotech and medical device companies. With the acquisition, AplusA plans to establish itself as a major player in the global market.
buyer: AplusA
AplusA is a reputable medical market research firm that specializes in international, primary research for the Pharmaceutical, Biotechnology and Medical Device Industries. For over 25 years, AplusA has been guiding lifecycle management of the most innovative healthcare products worldwide. "
target: Bell Falla & Associates LLC
Bell Falla & Associates is an international market research and consulting firm for pharmaceutical, biotech and medical device companies. They provide both qualitative and quantitative research using state of the art research methodologies, as well as statistical consulting and marketing consulting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/11/2019 via PR Newswire

Corrona, Inc., acquired HealthiVibe LLC

synopsis: Corrona, LLC, a leading provider of real-world observational and syndicated registry data, announced that it has acquired HealthiVibe, LLC, a leading patient experience company. HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle.
buyer parent: Great Point Partners
buyer: Corrona, Inc.
Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators. "
target: HealthiVibe LLC
HealthiVibe uses a systematic, evidence-based process to help pharmaceutical clients spearhead patient engagement initiatives of the product lifecycle. They leverage models and online analytic platforms to provide tools to optimize clinical trials and enhance product commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/26/2020 via PR Newswire

Arsenal Capital Partners, acquired BresMed Health Solutions Ltd

synopsis: Arsenal Capital Partners, a leading private equity firm investing in healthcare and specialty industrials companies, announced the acquisition of BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry.
buyer: Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle‐market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, and completed more than 45 platform investments. "
target: BresMed Health Solutions Ltd
BresMed is a health economic and outcomes research consultancy that provides health economic solutions to the global pharmaceutical industry. Established in 2006, BresMed has more than 150 staff across offices in the U.K., Ireland, the Netherlands, the U.S., and India.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/26/2005 via PR Newswire

Greenfield Online, Inc., acquired Rapidata.net, Inc.

synopsis: Greenfield Online, Inc SRVY, a leading provider of Internet survey solutions to marketing research and consulting companies, today announced it has completed the acquisition of Rapidata.net, Inc., a privately-held North Carolina corporation, for $5.5 million in cash, subject to certain post closing adjustments.
buyer: Greenfield Online, Inc. (SRVY:$0.00)
Greenfield Online, Inc. is a global interactive media and services company that collects consumer attitudes about products and services, enabling consumers to reach informed purchasing decisions about the products and services they want to buy; and helping companies better understand their customer."
target: Rapidata.net, Inc.
Founded fifteen years ago by research pharmacist and professor David P. Lipson, R.PH., Ph.D., Rapidata.net connects pharmaceutical market researchers to healthcare providers and their patients. This connection allows pharmaceutical market researchers to learn more about the prescription medications
price ($mm)
$5.50
rev ($mm)
$2
EBITDA ($mm)
EV / rev
2.6x
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/19/2013 via BusinessWire

Halifax Group, acquired Envision Pharma, Inc.

synopsis: The Halifax Group, a leading middle-market private equity firm, announced that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries.
buyer: Halifax Group
The Halifax Group is a private equity firm that invests between $10 and $40 million alongside owners and managers of established, growing and profitable companies that are leaders in their market niche. "
target parent: Express Scripts Inc.
target: Envision Pharma, Inc.
Envision Pharma, founded in 2001, is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/18/2011 via BNC Analysis

United BioSource Corporation, acquired Arrowhead Electronic Healthcare

synopsis: Bracket, a division of United BioSource Corp. has acquired Arrowhead Electronic Healthcare, a privately-held electronic patient-reported outcome (ePRO) technologies company. Its ePRO-LOG software platform is used in more than 60 countries on smart phones, tablet computers, the Web and text-messaging apps.
buyer parent: Medco Health Solutions, Inc.
buyer: United BioSource Corporation
United BioSource Corporation (UBC) is a global scientific and medical affairs organization comprised of over 1,400 colleagues who design and execute product development and commercialization programs for clients throughout the industry. "
target: Arrowhead Electronic Healthcare
Arrowhead Electronic Healthcare is an electronic patient-reported outcome (ePRO) technologies company. The company advances patient-centric medical decisions by pioneering software solutions that capture and report real-time patient experiences using smartphones, Web, Tablet computers, and SMS.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/18/2009 via BusinessWire

United BioSource Corporation, acquired Healthcare Project Management

synopsis: United BioSource Corporation has announced the acquisition of HPM (Geneva) SA, a Geneva, Switzerland-based provider of drug safety and pharmacovigilance services, further extending UBC’s reach into the European market.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Healthcare Project Management
Healthcare Project Management (HPM) is a contract research organization founded in 1997 to provide clinical research services to industry as well as academia. Our core services are drug safety, medical writing and scientific consultancy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/7/2006 via Company Press Release

United BioSource Corporation, acquired BioCor LLC

synopsis: United BioSource Corporation acquired BioCor LLC, a provider of clinical data services to the pharmaceutical and biotechnology industries. BioCor delivers dedicated clinical data services and medical writing capabilities to support the regulatory approval process for new drugs.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioCor LLC
BioCor provides clinical data services, biostatistics, and medical writing to the pharmaceutical and biotechnology industries. The company is based in Yardley, Pennsylvania.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/6/2006 via

United BioSource Corporation, acquired BioNiche Global Learning

synopsis: United BioSource Corporation has acquired Bioniche Global Learning, a McLean, Virginia-based provider of training and education services to the pharmaceutical and biotechnology industries. Bioniche specializes in developing and implementing international programs for training health care professionals who serve as investigators in clinical research
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioNiche Global Learning
Bioniche Global Learning provides domestic and international rater training and other clinical trial and CME related educational services to the pharmaceutical and biotechnology industries. The Company specializes in psychiatry and other central nervous system diseases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/24/2006 via PR Newswire

United BioSource Corporation, purchased iLearn, an Advanced Learning Management System from IQ Consultancy Group

synopsis: United BioSource Corporation (UBC) today announced the acquisition of iLearn, an Advanced Learning Management System developed by the UK-based provider of eContent solutions, IQ Consultancy. The robust web-based technology allows UBC to offer new enterprise learning services to pharmaceutical and biotechnology clients.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
seller: IQ Consultancy Group
IQ Consultancy Group is an independent provider of eContent solutions, knowledge management solutions and project management services for e-Business. The company is based in Warrington, United Kingdom.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/17/2006 via PR Newswire

United BioSource Corporation, acquired MetaWorks, Inc.

synopsis: United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MetaWorks, Inc.
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/20/2004 via BusinessWire

United BioSource Corporation, acquired MEDTAP International, Inc.

synopsis: United BioSource Corp. formed in early 2003 to provide science and evidence based services and information to the pharmaceutical and life sciences industries, announced that it has acquired MEDTAP International, Inc., a Bethesda, Md.-based provider of health economics and outcomes research services for the pharmaceutical and biotechnology industry.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MEDTAP International, Inc.
MEDTAP(R) International, Inc. is a global health services research firm that conducts patient reported outcomes studies, economic evaluation and modeling studies, policy research and analysis for pharmaceutical companies, managed care organizations, biotechnology firms, medical device and diagnosti
price ($mm)
$14
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
closed 11/30/2009 via BusinessWire

PPD, Inc., acquired BioDuro, LLC

synopsis: PPD, Inc. announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: BioDuro, LLC
BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of over 630 in Beijing, China. Our priority is providing the highest quality, FDA-compliant services at an affordable cost.
price ($mm)
$49
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

Chiltern International Inc., acquired Vigiun

synopsis: Chiltern International Limited, a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paulo, Brazil.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Vigiun
Vigiun is a full service clinical research organization located in Sao Paulo, Brazil.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2009 via BNC Analysis

JLL Partners, acquired Patheon, Inc.

synopsis: JLL Partners Inc. has become the majority shareholder of Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: Patheon, Inc.
Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnology companies.
price ($mm)[EV]
$89 [$300]*
rev ($mm)
$628
EBITDA ($mm)
$82
EV / rev
1.0x
EV / EBITDA
7.4x
closed 2/26/2009 via PR Newswire

ChanTest Corporation, acquired Applied Cell Sciences

synopsis: The leading experts in ion channels and G-protein coupled receptors - key to drug discovery, development, and safety - are now united. ChanTest, the leading provider of ion channel testing services and validated cell lines, announced that it has acquired Rockville, Maryland-based Applied Cell Sciences. ACS is a contract research organization.
buyer: ChanTest Corporation
ChanTest has developed the world’s most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. "
target: Applied Cell Sciences
Applied Cell Sciences delivers high throughput screening reagents and reagent-development services for drug discovery research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/6/2009 via BusinessWire

WIL Research Laboratories, LLC, acquired Midwest BioResearch, LLC

synopsis: WIL Research Laboratories, LLC and WIL Research Holding Company, Inc. announce the acquisition of Midwest BioResearch, LLC. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.
buyer: WIL Research Laboratories, LLC
WIL Research Laboratories, LLC is a contract research organization that provides an interdisciplinary approach to non-clinical toxicology, pharmacology, metabolism and both clinical and non-clinical bioanalytical services. "
target: Midwest BioResearch, LLC
Midwest BioResearch, LLC was founded in 2003 by scientists, directors and managers from major pharmaceutical companies to provide drug disposition and toxicology services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA

Like Cognitive Drug Research, Ltd.


read more

Cognitive Drug Research, Ltd.

Corrona, Inc.

Symphony Health Solutions

Kalorama Information

Health Strategies Group

Metanexgen, Inc.

DoctorDirectory.com

Carson Analytics

MD Mindset, LLC

AlphaDetail, Inc.

Bell Falla & Associates LLC

HealthiVibe LLC

CenterWatch, Inc.

ERT

ERT

CenterWatch, Inc.

CenterWatch, Inc.

Advarra

BresMed Health Solutions Ltd

Rapidata.net, Inc.

read more

Cognitive Drug Research, Ltd.

read more

Envision Pharma, Inc.

Arrowhead Electronic Healthcare

Cognitive Drug Research, Ltd.

Healthcare Project Management

Envision Pharma, Inc.

BioCor LLC

BioNiche Global Learning

IQ Consultancy Group

MetaWorks, Inc.

MEDTAP International, Inc.

read more

Bio-Quant, Inc.

BioDuro, LLC

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Vigiun

Patheon, Inc.

Applied Cell Sciences

Midwest BioResearch, LLC

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

Geography
Matching Companies
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch